We then employed pharmacological intervention, AAV-mediated overexpression, and nongenome editing CRISPR gene activation to demonstrate the benefit of targeting CEBPA and downstream pathways in alleviating experimental lung fibrosis, supporting CEBPA as a key regulator of tissue homeostasis and repair in the lung. Here, CEBPA is linked to pulmonary fibrosis.